Evidence map›Paper›PMID 37602341›Full record

ArticleInternational journal of ophthalmology2023

Evaluation of trabecular meshwork-specific promoters

Jun-Kai Tan, Ying Xiao, Guo Liu, Long-Xiang Huang, Wen-Hao Ma, Yan Xia, Xi-Zhen Wang, Xian-Jun Zhu, Su-Ping Cai, Xiao-Bing Wu and 2 more

Open access · goldAbstract read
In one paragraph

Article in International journal of ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Jun-Kai TanXiamen Eye Center, Xiamen University, Xiamen 361004, Fujian Province, China.
Ying XiaoDepartment of Pathology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610032, Sichuan Province, China.
Guo LiuSichuan Provincial Key Laboratory for Human Disease Gene Study, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, Sichuan Province, China.
Long-Xiang HuangThe First Affiliated Hospital of Fujian Medical University, Fuzhou 350004, Fujian Province, China.
Wen-Hao MaBeijing FivePlus Molecular Medicine Institute Co., Ltd., Beijing 102600, China.
Yan XiaBeijing FivePlus Molecular Medicine Institute Co., Ltd., Beijing 102600, China.
Xi-Zhen WangShenzhen Key Laboratory of Ophthalmology, Shenzhen Eye Hospital, School of Optometry, Jinan University, Shenzhen 518040, Guangdong Province, China.
Xian-Jun ZhuSichuan Provincial Key Laboratory for Human Disease Gene Study, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, Sichuan Province, China.
Su-Ping CaiShenzhen Key Laboratory of Ophthalmology, Shenzhen Eye Hospital, School of Optometry, Jinan University, Shenzhen 518040, Guangdong Province, China.
Xiao-Bing WuBeijing FivePlus Molecular Medicine Institute Co., Ltd., Beijing 102600, China.
Yun WangShenzhen Key Laboratory of Ophthalmology, Shenzhen Eye Hospital, School of Optometry, Jinan University, Shenzhen 518040, Guangdong Province, China.
Xu-Yang LiuXiamen Eye Center, Xiamen University, Xiamen 361004, Fujian Province, China.
Jinan University · CNUniversity of Electronic Science and Technology of China · CNFujian Medical University · CNXiamen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo evaluate the potential of two trabecular meshwork (TM)-specific promoters, Chitinase 3-like 1 (Ch3L1) and matrix gla protein (MGP), for improving specificity and safety in glaucoma gene therapy based on self-complementary AAV2 (scAAV2) vector technologies.

methodsAn scAAV2 vector with C3 transferase (C3) as the reporter gene (scAAV2-C3) was selected. The scAAV2-C3 vectors were driven by Ch3L1 (scAAV2-Ch3L1-C3), MGP (scAAV2-MGP-C3), enhanced MGP (scAAV2-eMGP-C3) and cytomegalovirus (scAAV2-CMV-C3), respectively. The cultured primary human TM cells were treated with each vector at different multiplicities of infections. Changes in cell morphology were observed by phase contrast microscopy. Actin stress fibers and Rho GTPases/Rho-associated protein kinase pathway-related molecules were assessed by immunofluorescence staining, real-time quantitative polymerase chain reaction and Western blot. Each vector was injected intracamerally into the one eye of each rat at low and high doses respectively.

resultsIn TM cell culture studies, the vector-mediated C3 expression induced morphologic changes, disruption of actin cytoskeleton and reduction of fibronectin expression in TM cells by inhibiting the Rho GTPases/Rho-associated protein kinase signaling pathway. At the same dose, these changes were significant in TM cells treated with scAAV2-CMV-C3 or scAAV2-Ch3L1-C3, but not in cells treated with scAAV2-eMGP-C3 or scAAV2-MGP-C3. At low-injected dose, the IOP was significantly decreased in the scAAV2-Ch3L1-C3-injected eyes but not in scAAV2-MGP-C3-injected and scAAV2-eMGP-C3-injected eyes. At high-injected dose, significant IOP reduction was observed in the scAAV2-eMGP-C3-injected eyes but not in scAAV2-MGP-C3-injected eyes. Similar to scAAV2-CMV-C3, scAAV2-Ch3L1-C3 vector showed efficient transduction both in the TM and corneal endothelium. In anterior segment tissues of scAAV2-eMGP-C3-injected eyes, no obvious morphological changes were found except for the TM. Inflammation was absent.

conclusionIn scAAV2-transduced TM cells, the promoter-driven efficiency of Ch3L1 is close to that of cytomegalovirus, but obviously higher than that of MGP. In the anterior chamber of rat eye, the transgene expression pattern of scAAV2 vector is presumably affected by MGP promoter, but not by Ch3L1 promoter. These findings would provide a useful reference for improvement of specificity and safety in glaucoma gene therapy using scAAV2 vector.

Indexed as

C3 transferasechitinase 3-like 1matrix gla proteinself-complementary AAV2trabecular meshwork

Identifiers

PMID37602341
PMCPMC10398517
OpenAlexW4385255657

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.